Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 Pathway in Advanced, Recurrent Endometrial Cancer: A Scoping Review with SWOT Analysis.

Cancers (Basel) · 2023 · PMC10527181 · PMID 37760602

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

While differences in the study’s primary endpoint (PFS) did not reach statistical significance, ORR was significantly improved and CA-125 levels were significantly lower in patients with FRα positive tumours in the mirvetuximab soravtansine group [ 106 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.